

# ASX Announcement



Medibio Limited – 26 October 2022

## MEDIBIO ANNOUNCES APPOINTMENT OF NON-EXECUTIVE CHAIR

**Melbourne, Australia and Minneapolis, MN – 26 October 2022: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCPINK: MDBIF)**, is pleased to announce the appointment of Mr David Trimboli currently Non-Executive Director (appointed on 25 August 2022) of the Company as the Company's new Non-Executive Chair.

Mr Trimboli is an experienced Chairperson and is considered independent and thus will bring an objective view to the Board in order to progress the Company's strategic objectives.

Mr Trimboli said: *"It is an honour to be appointed Chair of Medibio and I look forward to further engaging with Medibio's stakeholders and to working with newly appointed CEO, Tom Young, and his leadership team, to deliver sustainable growth for all stakeholders. Medibio's recognises the need for improved performance and will focus on implementing and executing our operational strategy."*

ENDS

*This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.*

### About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Melbourne (Vic) and Minneapolis (MN). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcm Markets.com](http://www.otcm Markets.com) and [www.asx.com.au](http://www.asx.com.au).

### Medibio Investor Enquiries:

Medibio Investor Relations  
[investors@medibio.com.au](mailto:investors@medibio.com.au)  
+61 3 9692 7222